Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria

被引：8

作者：

Arizpe, Andre ^{[1
]}

Reveles, Kelly R. ^{[1
,2
]}

Patel, Shrina D. ^{[3
]}

Aitken, Samuel L. ^{[3
,4
]}

机构：

[1] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA

[2] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA

[3] Univ Texas MD Anderson Canc Ctr, Div Pharm, 1515 Holcombe Blvd,Unit 0090, Houston, TX 77030 USA

[4] UTHlth McGovern Sch Med, Ctr Antimicrobial Resistance & Microbial Genom, Houston, TX 77030 USA

来源：

CURRENT INFECTIOUS DISEASE REPORTS | 2016年 / 18卷 / 12期

关键词：

Extended-spectrum beta-lactamase; Pseudomonas aeruginosa; Cefepime; Piperacillin-tazobactam; Carbapenem; Ceftolozane-tazobactam; Ceftazidime-avibactam; SPECTRUM-BETA-LACTAMASE; BLOOD-STREAM INFECTIONS; CEFTAZIDIME-AVIBACTAM ACTIVITY; US MEDICAL-CENTERS; IN-VITRO ACTIVITY; PSEUDOMONAS-AERUGINOSA INFECTION; URINARY-TRACT-INFECTIONS; EXTENDED-SPECTRUM; ESCHERICHIA-COLI; PIPERACILLIN-TAZOBACTAM;

D O I：

10.1007/s11908-016-0552-7

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Resistance to cephalosporins is now common among Gram-negative bacterial infections, including those caused by the Enterobacteriaceae and Pseudomonas aeruginosa, posing a major threat to public health. As resistance to the traditional drugs of choice for these infections, carbapenems, has also become increasingly common, interest in cefepime and piperacillin-tazobactam as carbapenemsparing alternatives has increased. Additionally, the availability of the novel beta-lactam-beta-lactamase inhibitor combinations ceftolozane-tazobactam and ceftazidime-avibactam has added to the antimicrobial armamentarium available to treat these multidrug-resistant infections. Here, we review the recent literature on the use of carbapenem-sparing alternatives and highlight the potential utility of novel antimicrobials.

引用

收藏

页数：12

相关论文

共 102 条

[1] High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center [J].

Aitken, Samuel L. ;

Tarrand, Jeffrey J. ;

Deshpande, Lalitagauri M. ;

Tverdek, Frank P. ;

Jones, Anne L. ;

Shelburne, Samuel A. ;

Prince, Randall A. ;

Bhatti, Micah M. ;

Rolston, Kenneth V. I. ;

Jones, Ronald N. ;

Castanheira, Mariana ;

Chemaly, Roy F. .

CLINICAL INFECTIOUS DISEASES, 2016, 63 (07) :954-958

[2] Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient [J].

Aitken, Samuel L. ;

Kontoyiannis, Dimitrios P. ;

DePombo, April M. ;

Bhatti, Micah M. ;

Tverdek, Frank P. ;

Gettys, Suzanne C. ;

Nicolau, David P. ;

Nunez, Cesar A. .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (09) :1040-1042

[3] Treatment of Extended-Spectrum Beta-Lactamase Enterobacteriaceae With Cefepime: The Dose Matters, Too [J].

Altshuler, Jerry ;

Aitken, Samuel L. ;

Guervil, David ;

Esaian, Diana ;

Papadopoulos, John ;

Arias, Cesar A. .

CLINICAL INFECTIOUS DISEASES, 2013, 57 (06) :915-916

[4] Secular Trends in Nosocomial Bloodstream Infections: Antibiotic-Resistant Bacteria Increase the Total Burden of Infection [J].

Ammerlaan, H. S. M. ;

Harbarth, S. ;

Buiting, A. G. M. ;

Crook, D. W. ;

Fitzpatrick, F. ;

Hanberger, H. ;

Herwaldt, L. A. ;

van Keulen, P. H. J. ;

Kluytmans, J. A. J. W. ;

Kola, A. ;

Kuchenbecker, R. S. ;

Lingaas, E. ;

Meessen, N. ;

Morris-Downes, M. M. ;

Pottinger, J. M. ;

Rohner, P. ;

dos Santos, R. P. ;

Seifert, H. ;

Wisplinghoff, H. ;

Ziesing, S. ;

Walker, A. S. ;

Bonten, M. J. M. .

CLINICAL INFECTIOUS DISEASES, 2013, 56 (06) :798-805

[5] Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms [J].

Bhat, Sunil V. ;

Peleg, Anton Y. ;

Lodise, Thomas P., Jr. ;

Shutt, Kathleen A. ;

Capitano, Blair ;

Potoski, Brian A. ;

Paterson, David L. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (12) :4390-4395

[6] n Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy [J].

Bremmer, Derek N. ;

Nicolau, David P. ;

Burcham, Pam ;

Chunduri, Anil ;

Shidham, Ganesh ;

Bauer, Karri A. .

PHARMACOTHERAPY, 2016, 36 (05) :E30-E33

[7] Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates [J].

Buehrle, Deanna J. ;

Shields, Ryan K. ;

Chen, Liang ;

Hao, Binghua ;

Press, Ellen G. ;

Alkrouk, Ammar ;

Potoski, Brian A. ;

Kreiswirth, Barry N. ;

Clancy, Cornelius J. ;

Nguyen, M. Hong .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) :3227-3231

[8] In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms [J].

Bulik, Catharine C. ;

Tessier, Pamela R. ;

Keel, Rebecca A. ;

Sutherland, Christina A. ;

Nicolaua, David P. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (01) :544-549

[9] Updated Functional Classification of β-Lactamases [J].

Bush, Karen ;

Jacoby, George A. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (03) :969-976

[10] Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study [J].

Carmeli, Yehuda ;

Armstrong, Jon ;

Laud, Peter J. ;

Newell, Paul ;

Stone, Greg ;

Wardman, Angela ;

Gasink, Leanne B. .

LANCET INFECTIOUS DISEASES, 2016, 16 (06) :661-673

← 1 2 3 4 5 6 7 8 9 10 →